Lys Pharmaceutical

Lys Pharmaceutical is a South Korean clinical-stage biotechnology company specializing in the development of first-in-class therapies for neurodegenerative and metabolic disorders. The company’s primary focus lies in overcoming the challenges of drug delivery to the central nervous system (CNS) using proprietary blood-brain barrier (BBB) penetration technologies. Its lead program, LYS001, is being developed for the treatment of Parkinson's disease, while other pipeline assets target Alzheimer's disease and metabolic dysfunction-associated steatohepatitis (MASH). By leveraging its expertise in molecular design and small molecule development, Lys Pharmaceutical aims to provide transformative treatments for patients with high unmet medical needs. The company is headquartered in Hanam, South Korea, and maintains a robust R&D focus on innovative drug discovery.